This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Merck Patent Gmbh. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Ulrike Dau: Innovator in Prostate Cancer Treatment
Introduction
Ulrike Dau is a prominent inventor based in Darmstadt, Germany. She has made significant contributions to the field of cancer treatment, particularly focusing on prostate cancer. Her innovative work has led to the development of a unique therapeutic approach that utilizes antibodies to combat this disease.
Latest Patents
Ulrike Dau holds a patent for an "Anti-alpha-V integrin antibody for the treatment of prostate cancer." This invention is directed towards treating prostate cancer through the administration of an anti-alpha-v integrin antibody. It specifically targets patients suffering from castration-resistant prostate cancer (CRPC), which may be accompanied by lymph node and bone tissue metastases (mCRPC). The therapy involves the use of the anti-angiogenic antibody DI17E6 and its structural mutants.
Career Highlights
Ulrike is associated with Merck Patent GmbH, where she continues to advance her research and development efforts. Her work is characterized by a commitment to improving treatment options for patients with prostate cancer.
Collaborations
Ulrike collaborates with notable colleagues, including Frederic Christian Pipp and Michael Zuehlsdorf. Their combined expertise contributes to the innovative approaches being developed in the field of cancer treatment.
Conclusion
Ulrike Dau's contributions to the treatment of prostate cancer through her patented innovations highlight her role as a leading inventor in the medical field. Her work not only advances scientific knowledge but also offers hope for improved patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile